LMR Partners’s Ginkgo Bioworks DNA Stock Holding History

LMR Partners’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,623	Closed	-$117K	–	1026
2023 Q3	$117K	Buy	1,623 +1,530	+1,645%	+$122K	﹤0.01%	668
2023 Q2	$6.88K	Buy	+93	New	+$5.5K	﹤0.01%	793

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LMR Partners's DNA Position: Q1 2022 in Review

LMR Partners sold out of Ginkgo Bioworks (DNA) in Q1 2022, closing a stake of 3,517 shares — an estimated $1.17M sold.

LMR Partners first reported a position in DNA in Q4 2021 and held it in 1 quarter. The position peaked at $1.17M in Q4 2021. 190 funds tracked by Wall St. Rank hold DNA as of Q1 2022.

LMR Partners reported no remaining Ginkgo Bioworks position as of Q1 2022 after selling out during the quarter.
LMR Partners sold 3,517 Ginkgo Bioworks shares in Q1 2022, an estimated $1.17M.
LMR Partners first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 1 quarter.
LMR Partners's Ginkgo Bioworks position peaked at $1.17M in Q4 2021.
190 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2022.

Based on LMR Partners's 13F filing for Q1 2022, filed 16 May 2022.